Shionogi and Sciele Announce Successful Tender Offer and Commencement of Subsequent Offering
06 Octubre 2008 - 5:30AM
Business Wire
On October�6,�2008, Shionogi & Co., Ltd. (�Shionogi�) and
Sciele Pharma, Inc. (�Sciele�) (NASDAQ: SCRX) announced the
successful completion of the tender offer by Shionogi�s indirect
wholly owned subsidiary, Tall Bridge, Inc. (�Purchaser�), to
acquire all outstanding shares of common stock of Sciele for $31.00
per share. The initial offering period expired, as scheduled, at
12:00 midnight, New York City time, on Friday, October 3, 2008. The
depositary for the tender offer has advised Shionogi that, as of
the expiration of the initial offering period, a total of
approximately 27,134,821 shares (excluding shares tendered through
notices of guaranteed delivery) were validly tendered to Purchaser
and not withdrawn, representing approximately 85.44% of the shares
outstanding. Additional shares were tendered through notices of
guaranteed delivery. Purchaser has accepted all shares that were
validly tendered during the initial offering period. Payment for
such shares will be made promptly, in accordance with the terms of
the offer. Shionogi also announced that Purchaser will provide a
subsequent offering period for all remaining shares of Sciele
common stock to permit stockholders who have not yet tendered their
shares to do so. This subsequent offering period will expire at
5:00 p.m., New York City time, on Wednesday, October 8, 2008. The
same $31.00 per share cash consideration offered during the initial
offering period will be paid to holders of Sciele�s common stock
who tender their shares during the subsequent offering period. The
procedures for tendering shares during the subsequent offering
period are the same as during the initial offering period, except
that (i) the guaranteed delivery procedures may not be used during
the subsequent offering period and (ii) shares tendered during the
subsequent offering period may not be withdrawn. Additional
Information and Where to Find It THIS ANNOUNCEMENT IS FOR
INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO
PURCHASE OR A SOLICITATION OF AN OFFER TO SELL SCIELE�S COMMON
STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER
STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER
OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) THAT WAS
FILED BY TALL BRIDGE, INC. WITH THE SECURITIES AND EXCHANGE
COMMISSION (SEC) ON SEPTEMBER 8, 2008. THESE MATERIALS, AS THEY MAY
BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION,
INCLUDING THE TERMS AND CONDITIONS OF THE OFFER, THAT SHOULD BE
READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE
TENDER OFFER. INVESTORS AND STOCKHOLDERS CAN OBTAIN A FREE COPY OF
THESE MATERIALS AND OTHER DOCUMENTS FILED BY TALL BRIDGE, INC. WITH
THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. THE
TENDER OFFER MATERIALS MAY ALSO BE OBTAINED FOR FREE BY CONTACTING
THE INFORMATION AGENT FOR THE TENDER OFFER, GEORGESON, AT
1-212-440-9800 FOR BANKS AND BROKERS AND 1-800-334-9586 FOR
SHAREHOLDERS AND ALL OTHERS, OR BY WRITING TO 199 WATER STREET,
26th FLOOR, NEW YORK, NY 10038. About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major research-driven Japanese
pharmaceutical manufacturer. The company�s primary businesses are
research and development, manufacturing, marketing, and import and
export sales of pharmaceuticals and diagnostics. Shionogi follows a
basic policy of continually providing the superior medicines
essential to people�s health. For more details, please visit
www.shionogi.co.jp. About Sciele Pharma, Inc. Sciele Pharma, Inc.
is a pharmaceutical company specializing in sales, marketing and
development of branded prescription products focused on the
therapeutic areas of Cardiovascular, Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular and Diabetes products
treat patients with high cholesterol, hypertension, high
triglycerides, unstable angina and Type 2 diabetes; its Women's
Health products are designed to improve the health and well-being
of women and mothers and their babies; and its Pediatrics products
treat allergies, asthma, coughs and colds, and attention deficit
and hyperactivity disorder (ADHD). The Company was founded in 1992
and is headquartered in Atlanta, Georgia. The Company employs more
than 1,000 people. The Company's success is based on placing the
needs of patients first, improving health and quality of life, and
implementing its business platform � an Entrepreneurial Spirit,
Innovation, Execution Excellence, Simplicity, and Teamwork. For
more information on Sciele, please visit www.sciele.com.
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024